The Lancet Gastroenterology &amp; Hepatology in conversation with – Details, episodes &amp; analysis

https://bsky.app/profile/lancetgastrohep.bsky.social

Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy

lundi 1 juillet 2024 • Duration 25:05

Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00084-0?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction

mercredi 13 septembre 2023 • Duration 16:31

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00191-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

jeudi 10 août 2023 • Duration 14:29

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00145-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease

mercredi 12 juillet 2023 • Duration 17:41

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00017-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis

mercredi 7 juin 2023 • Duration 12:48

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00098-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Adelina Artenie on the incidence of HIV and HCV in people who inject drugs

mercredi 10 mai 2023 • Duration 17:15

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00018-3/fulltext?dgcid=buzzsprout_icw_podcast_langas_lancet

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Johan Burisch on the costs of inflammatory bowel disease in high-income settings

mercredi 12 avril 2023 • Duration 20:00

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.

Read the Commission here:
The cost of inflammatory bowel disease in high-income settings

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

mercredi 8 février 2023 • Duration 21:30

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.

Read the full article:
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer

lundi 23 janvier 2023 • Duration 20:20

Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma.

Read the full article:
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)

Continue this conversation on social!